Transcode Therapeutics Valuation
| RNAZ Stock | USD 3.35 0.16 5.02% |
At this time, the company appears to be undervalued. Transcode Therapeutics has a current Real Value of $7.48 per share. The regular price of the company is $3.35. Our model measures the value of Transcode Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 1.99 %, shares outstanding of 696.25 K, and Return On Equity of -10.49 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Transcode Therapeutics' valuation include:
Undervalued
Today
Please note that Transcode Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Transcode Therapeutics is based on 3 months time horizon. Increasing Transcode Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Transcode Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Transcode Stock. However, Transcode Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.35 | Real 7.48 | Target 20.0 | Hype 2.41 |
The intrinsic value of Transcode Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Transcode Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Transcode Therapeutics helps investors to forecast how Transcode stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Transcode Therapeutics more accurately as focusing exclusively on Transcode Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Transcode Therapeutics' intrinsic value based on its ongoing forecasts of Transcode Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Transcode Therapeutics' closest peers.
Transcode Therapeutics Cash |
|
Transcode Valuation Trend
Analysing the historical paterns of Transcode Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Transcode Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Transcode Valuation Data Drivers
Transcode Therapeutics Total Value Analysis
Transcode Therapeutics is at this time forecasted to have valuation of 609.05 K with market capitalization of 2.33 M, debt of 450.57 K, and cash on hands of 13.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Transcode Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
609.05 K | 2.33 M | 450.57 K | 13.45 M |
Transcode Therapeutics Asset Utilization
One of the ways to look at asset utilization of Transcode is to check how much profit was generated for every dollar of assets it reports. Transcode Therapeutics has a negative utilization of assets of -2.08 %, losing $0.0208 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Transcode Therapeutics shows how discouraging it operates for each dollar spent on its assets.Transcode Therapeutics Ownership Allocation
About 98.0 % of Transcode Therapeutics outstanding shares are held by general public with 0.009 (%) owned by insiders and only 1.99 % by institutional holders.Transcode Therapeutics Profitability Analysis
Net Loss for the year was (18.55 M) with profit before overhead, payroll, taxes, and interest of 0.About Transcode Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Transcode Therapeutics. We calculate exposure to Transcode Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Transcode Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -465.1 K | -441.8 K |
Transcode Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 179 K |
Transcode Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Transcode Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Transcode we look at many different elements of the entity such as Transcode's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Transcode Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Transcode Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Transcode Therapeutics' worth.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.